13 results about "Routine laboratory" patented technology

This invention provides a negative pressure isolation live microscope experimental box. The experimental box, through its closed negative pressure design, ensures the biosafety of experiments with pathogens of BSL-2 level and above, meeting the requirements of the safety committee review. At the same time, its innovative box-type integrated window structure eliminates the vibration torque caused by animal movement in traditional suspended windows from a mechanical design perspective, providing unparalleled stability for high-precision imaging. Ultimately, it makes it possible to safely and stably conduct live microscopic studies of highly pathogenic infection models in a conventional laboratory.

The application discloses a triple fluorescent quantitative PCR detection kit for simultaneously detecting CHIKV, BFV and RRV, which contains a specific primer probe composition for simultaneously detecting chikungunya virus, Barmah Forest virus and Ross River virus, can simultaneously detect three viruses which are transmitted by insect vectors and cause acute fever with arthralgia symptoms in human beings in one PCR reaction tube, and has excellent specificity and repeatability, and is suitable for routine laboratory diagnosis of suspected samples of alphavirus infection, and provides a rapid and accurate detection method for the epidemiological study of CHIKV, BFV and RRV.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

Predicting treatment benefits of immune checkpoint inhibitor drugs (ICIs) without resorting to advanced genomic or immunologic assays is a major unmet clinical need. This disclosure provides a predictive model using machine-learning approaches based on routine laboratory test results in clinical practice.

The application discloses a novel autoantibody combination for idiopathic retroperitoneal fibrosis and diagnostic and monitoring applications thereof. The application screens and verifies five iRPF-specific autoantibodies, including anti-RBPJ antibody, anti-TPM1 antibody, anti-C1D antibody, anti-NPM1 antibody, anti-IL-1A antibody, and IgG4 subtypes of the above antibodies; the autoantibodies are significantly increased in iRPF patients and have a medium and above ability to identify iRPF, wherein the anti-C1D antibody can effectively distinguish iRPF from RPS; and the anti-TPM1, NPM1 and RBPJ antibodies can also be used for disease activity monitoring. The screened autoantibodies directly reflect the autoimmune nature of iRPF, have higher specificity than existing laboratory indicators, can be detected by conventional laboratory equipment, have low cost and good promotion, and have good clinical application prospects.

The application relates to application of CTRP4 in condition assessment and treatment of herpes simplex encephalitis, belongs to the technical field of biological medicine, and solves one of the problems that the condition assessment of HSE in the prior art is highly subjective, an imaging examination cannot reflect intracranial core lesions in real time and dynamically, is not related to a core biological mechanism of a disease, brain tissue samples are difficult to obtain, direct and effective indexes of intracranial disease states are scarce, and routine laboratory examinations are not specific for central nervous system pathologies and recovery of nerve functions. The application comprises application of CTRP4 in preparation of a herpes simplex encephalitis diagnostic reagent, and the diagnostic reagent is used for detecting the expression level of CTRP4 in a biological sample of a subject. The application of CTRP4 in preparation of the herpes simplex encephalitis diagnostic reagent can provide a highly specific, non-invasive and dynamic herpes simplex encephalitis condition assessment scheme, and solves the limitation problem of subjective diagnosis by doctors in traditional assessment.

The invention discloses a biomarker MYD88 for evaluating visceral obesity and application of the biomarker MYD88, and belongs to the technical field of biomedical detection and molecular marker research. The marker is MYD88 in serum, the biomarker is serum protein MYD88, in the evaluation process, only a serum sample is needed, detection can be completed under conventional laboratory conditions based on serum protein detection, the specificity is high, operation is easy and convenient, cost is low, non-invasive performance is achieved, and the method is suitable for obesity typing screening and evaluation of large-scale people and has good application prospects. The method has the potential of wide popularization and application, provides a theoretical basis and a practical basis for early diagnosis and accurate intervention of visceral obesity, and effectively overcomes the limitation of an existing method.

The invention discloses an optimization method and system for a diabetic complication prediction model, and the method comprises the steps: collecting conventional laboratory detection index data of a diabetic patient, carrying out the preprocessing of missing value elimination, label merging, SMOTE resampling, and the like, and constructing a balanced data set; in combination with the average importance of various machine learning model evaluation indexes, screening out a key feature subset; a random forest, an XGBoost, a support vector machine and a multi-layer perceptron are selected as base classifiers, a stacked integrated learning model is constructed after hyper-parameter optimization, and the prediction performance is further improved; and finally, the model is packaged into API service and embedded into a hospital information system, so that high-precision, low-cost and real-time risk prediction of diabetic complications is realized. Experimental results show that the accuracy rate of predicting diabetic nephropathy complications reaches 98.5%, the AUC reaches 99.76%, and the method is superior to a single model.

The invention relates to a portable non-source program cooling instrument and a rapid cold exchange system thereof, and belongs to the technical field of biological sample deep hypothermia preservation. The portable non-source programmed cooling instrument comprises a composite heat preservation cavity and an intelligent monitoring unit, the composite heat preservation cavity comprises an outer shell, a middle-layer heat preservation shell and an inner-layer bearing inner container, a liquid nitrogen adsorption core material module is arranged in the bearing inner container and used for adsorbing liquid nitrogen and providing a cold source, and the intelligent monitoring unit is used for monitoring the temperature of the liquid nitrogen adsorption core material module. A sample cabin is arranged in the liquid nitrogen adsorption core material module. Under the condition of not depending on electric power, liquid nitrogen pipelines and other external auxiliary equipment, controllable low-speed / vitrification cryopreservation and transfer of biological samples such as microorganisms, cells and tissues can be conveniently achieved, and the requirements for high-quality cryopreservation and transfer of the biological samples under the conditions of outdoor sampling, conventional laboratories without special equipment and the like can be met.

The invention provides a method for rapidly measuring the external reflux ratio of a sewage plant, and solves the problem that the external reflux ratio is difficult to accurately estimate due to the lack of a flowmeter and difficulty in maintenance in the prior art. The method comprises the following steps: collecting external reflux sludge, continuously sampling for three times at a reflux pump outlet pipeline sampling point or a secondary sedimentation tank sludge reflux channel, sampling for five hundred milliliters each time, and uniformly mixing to obtain a sample to be detected; the method comprises the following steps: collecting sludge in an anaerobic tank, selecting three points along the length direction of the tank, and mixing by adopting a multi-point mixed sampling method to obtain a sample to be detected; and measuring the concentration according to a gravimetric method. And the external reflux ratio is obtained based on a calculation method derived based on a material balance principle. The method does not need to additionally purchase equipment, depends on conventional laboratory equipment, consumes no more than four hours for single-group testing, is suitable for sewage plants of the AO process and derivative processes thereof, has the advantages of high efficiency, economy, high universality and accurate result, and can provide reliable basis for process regulation and control of the sewage plants.

The invention discloses a fluorescence detection method for exosome drug loading efficiency based on low-speed centrifugal separation. The method comprises the following steps: separating an exosome from a biological sample through low-speed centrifugation; labeling the drug with a fluorescent dye, and carrying the drug through a co-incubation or ultrasonic method; purifying the drug-loaded exosome by adopting low-speed centrifugation; and measuring the fluorescence intensity by using a fluorospectro photometer, and calculating the drug loading efficiency through a standard curve. According to the method, equipment is simple, operation is convenient, and rapid and low-cost detection can be achieved; by adopting low-speed centrifugal separation of the exosome and combining a fluorescence labeling technology, the equipment dependence and the operation complexity are reduced, so that a conventional laboratory without ultracentrifugation and liquid chromatography equipment can also efficiently detect the drug loading efficiency of the exosome, thereby solving the problems of high equipment requirement and complicated operation in the prior art, and improving the detection efficiency of the exosome. Meanwhile, the method is simple in step and easy to implement, and professional training requirements are reduced.

The invention discloses a biomarker CTNNA1 for evaluating visceral obesity and application of the biomarker CTNNA1, and belongs to the technical field of biomedical detection and molecular marker research. The marker is CTNNA1 in serum, the biomarker is serum protein CTNNA1, in the evaluation process, only a serum sample is needed, detection can be completed under conventional laboratory conditions based on serum protein detection, specificity is high, operation is easy and convenient, cost is low, non-invasive performance is achieved, and the method is suitable for obesity typing screening and evaluation of large-scale people and has good application prospects. The method has the potential of wide popularization and application, provides a theoretical basis and a practical basis for early diagnosis and accurate intervention of visceral obesity, and effectively overcomes the limitation of an existing method.

The invention discloses a biomarker GKN2 for evaluating visceral obesity and application of the biomarker GKN2, and belongs to the technical field of biomedical detection and molecular marker research. The marker is GKN2 in serum, the biomarker is serum protein GKN2, only a serum sample is needed in the evaluation process, detection can be completed under conventional laboratory conditions on the basis of serum protein detection, and the method is high in specificity, easy and convenient to operate, low in cost, non-invasive, suitable for obesity typing screening and evaluation of large-scale people and high in practicability. The method has the potential of wide popularization and application, provides a theoretical basis and a practical basis for early diagnosis and accurate intervention of visceral obesity, and effectively overcomes the limitation of an existing method.